439 related articles for article (PubMed ID: 16643517)
1. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.
Turnidge J; Kahlmeter G; Kronvall G
Clin Microbiol Infect; 2006 May; 12(5):418-25. PubMed ID: 16643517
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.
Kronvall G; Karlsson I; Walder M; Sörberg M; Nilsson LE
J Antimicrob Chemother; 2006 Mar; 57(3):498-505. PubMed ID: 16410264
[TBL] [Abstract][Full Text] [Related]
3. Population distributions of minimum inhibitory concentration--increasing accuracy and utility.
Lambert RJ; Lambert R
J Appl Microbiol; 2006 May; 100(5):999-1010. PubMed ID: 16630000
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility testing of lactic acid bacteria and bifidobacteria by broth microdilution method and Etest.
Kushiro A; Chervaux C; Cools-Portier S; Perony A; Legrain-Raspaud S; Obis D; Onoue M; van de Moer A
Int J Food Microbiol; 2009 Jun; 132(1):54-8. PubMed ID: 19361877
[TBL] [Abstract][Full Text] [Related]
5. Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables.
Hammel JP; Bhavnani SM; Jones RN; Forrest A; Ambrose PG
Antimicrob Agents Chemother; 2006 Jan; 50(1):62-7. PubMed ID: 16377668
[TBL] [Abstract][Full Text] [Related]
6. Statistical properties and inference of the antimicrobial MIC test.
Annis DH; Craig BA
Stat Med; 2005 Dec; 24(23):3631-44. PubMed ID: 16217851
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
9. Estimation of the wild-type minimum inhibitory concentration value distribution.
Jaspers S; Aerts M; Verbeke G; Beloeil PA
Stat Med; 2014 Jan; 33(2):289-303. PubMed ID: 23946200
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
11. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
12. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
16. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of MIC determination for Streptococcus pneumoniae using the Sirscan2000automatic MIC determination system.
Grohs P; Janoir C; Grondin S; Simon S; Bonnet G; Henry L; Gutmann L; Varon E
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):399-403. PubMed ID: 21683271
[TBL] [Abstract][Full Text] [Related]
18. Statistical modelling of Poisson/log normal data.
Miller G
Radiat Prot Dosimetry; 2007; 124(2):155-63. PubMed ID: 17223632
[TBL] [Abstract][Full Text] [Related]
19. Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function.
Viberg A; Cars O; Karlsson MO; Jönsson S
J Clin Pharmacol; 2008 Nov; 48(11):1270-81. PubMed ID: 18974282
[TBL] [Abstract][Full Text] [Related]
20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
